

Peter Albers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3232422/publications.pdf>

Version: 2024-02-01

319
papers

12,964
citations

32410

55
h-index

34195

103
g-index

355
all docs

355
docs citations

355
times ranked

10163
citing authors

#	ARTICLE	IF	CITATIONS
1	A Symplectic Dynamics Proof of the Degree-Genus Formula. Arnold Mathematical Journal, 2023, 9, 41-68.	0.2	2
2	Pseudorotations of the -disc and Reeb flows on the -sphere. Ergodic Theory and Dynamical Systems, 2022, 42, 402-436.	0.4	2
3	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. European Urology Oncology, 2022, 5, 285-295.	2.6	4
4	The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas. Molecular Oncology, 2022, 16, 982-1008.	2.1	10
5	Late relapsing germ cell tumors with elevated tumor markers. World Journal of Urology, 2022, 40, 363-371.	1.2	6
6	Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers. Journal of Urology, 2022, 207, 617-626.	0.2	2
7	Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND). World Journal of Urology, 2022, 40, 349-354.	1.2	6
8	Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights. Clinical Epigenetics, 2022, 14, 5.	1.8	14
9	Value of T_2 Mapping MRI for Prostate Cancer Detection and Classification. Journal of Magnetic Resonance Imaging, 2022, 56, 413-422.	1.9	8
10	A randomized trial of risk-adapted screening for prostate cancer in young men—Results of the first screening round of the PROBASE trial. International Journal of Cancer, 2022, 150, 1861-1869.	2.3	23
11	Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review. World Journal of Urology, 2022, 40, 2843-2852.	1.2	4
12	Age-stratified outcomes after radical prostatectomy in a randomized setting (LAP-01): do younger patients have more to lose?. World Journal of Urology, 2022, 40, 1151-1158.	1.2	4
13	Cognitive function in patients undergoing cystectomy for bladder cancer – results from a prospective observational study. Therapeutic Advances in Urology, 2022, 14, 175628722210876.	0.9	2
14	First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment. World Journal of Urology, 2022, , 1.	1.2	1
15	The PRIMETEST trial: Prospective phase II trial of primary retroperitoneal lymph node dissection (RPLND) in stage II A/B patients with seminoma.. Journal of Clinical Oncology, 2022, 40, 420-420.	0.8	12
16	Robotic-assisted Versus Laparoscopic Radical Prostatectomy: 12-month Outcomes of the Multicentre Randomised Controlled LAP-01 Trial. European Urology Focus, 2022, 8, 1583-1590.	1.6	14
17	Special Issue on Testis Cancer. World Journal of Urology, 2022, 40, 305-306.	1.2	1
18	Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01). Prostate, 2022, 82, 894-903.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. <i>World Journal of Urology</i> , 2022, 40, 1505-1512.	1.2	12
20	Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011. <i>European Urology Focus</i> , 2022, 8, 646-647.	1.6	7
21	How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence. <i>World Journal of Urology</i> , 2022, 40, 2863-2878.	1.2	7
22	Need for organ preservation in postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5031-5031.	0.8	0
23	Short-term and long-term outcomes after resection of thoracic growing teratoma syndrome. <i>World Journal of Urology</i> , 2021, 39, 2579-2585.	1.2	2
24	Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. <i>World Journal of Urology</i> , 2021, 39, 65-72.	1.2	2
25	Molecular and epigenetic pathogenesis of germ cell tumors. <i>Asian Journal of Urology</i> , 2021, 8, 144-154.	0.5	21
26	Surgical treatment of metastatic germ cell cancer. <i>Asian Journal of Urology</i> , 2021, 8, 155-160.	0.5	3
27	Re: The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis. <i>European Urology</i> , 2021, 79, 160-161.	0.9	0
28	Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. <i>Urologia Internationalis</i> , 2021, 105, 169-180.	0.6	37
29	Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II – Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy. <i>Urologia Internationalis</i> , 2021, 105, 181-191.	0.6	19
30	The pioneer and differentiation factor FOXA2 is a key driver of yolk sac tumour formation and a new biomarker for paediatric and adult yolk sac tumours. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1394-1405.	1.6	21
31	Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten –™s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1273-1274.	1.2	0
32	Solving problems is smart, preventing them is wise: Lessons learned from the 2nd International DKFZ Conference on Cancer Prevention. <i>International Journal of Cancer</i> , 2021, 148, 3086-3096.	2.3	1
33	Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>European Urology</i> , 2021, 79, 327-329.	0.9	54
34	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 525-537.	5.1	225
35	Testicular germ cell tumors. <i>Asian Journal of Urology</i> , 2021, 8, 143.	0.5	0
36	Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01). <i>European Urology</i> , 2021, 79, 750-759.	0.9	54

#	ARTICLE	IF	CITATIONS
37	ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. <i>Nature</i> , 2021, 595, 432-437.	13.7	293
38	Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, René Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>Eur Urol</i> 2021;79:327-329: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy. <i>European Urology</i> , 2021, 80, e28-e29.	0.9	0
39	Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. <i>European Urology</i> , 2021, 80, 4-6.	0.9	6
40	A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 731-739.	2.6	51
41	Virtual Conferences and the COVID-19 Pandemic: Are We Missing Out with an Online Only Platform?. <i>European Urology</i> , 2021, 80, 127-128.	0.9	17
42	Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection – A 13-year follow-up analysis of a phase III trial cohort. <i>European Journal of Cancer</i> , 2021, 155, 64-72.	1.3	10
43	The developmental origin of cancers defines basic principles of cisplatin resistance. <i>Cancer Letters</i> , 2021, 519, 199-210.	3.2	17
44	Addressing Equality of Representation in Urology Societies. <i>European Urology</i> , 2021, 80, 454-455.	0.9	4
45	Comparison and prediction of artefact severity due to total hip replacement in 1.5T versus 3T MRI of the prostate. <i>European Journal of Radiology</i> , 2021, 144, 109949.	1.2	12
46	On the Geometric Mechanics of Assignment Flows for Metric Data Labeling. <i>Lecture Notes in Computer Science</i> , 2021, , 398-410.	1.0	3
47	Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 441-447.	0.7	19
48	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020, 38, 1959-1968.	1.2	22
49	Clinical dilemmas in local and regional testis cancer. <i>Canadian Urological Association Journal</i> , 2020, 15, E58-E64.	0.3	1
50	Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. <i>Journal of Personalized Medicine</i> , 2020, 10, 270.	1.1	7
51	CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms. <i>British Journal of Cancer</i> , 2020, 123, 378-391.	2.9	30
52	A Canadian approach to the regionalization of testis cancer: A review. <i>Canadian Urological Association Journal</i> , 2020, 14, 346-351.	0.3	0
53	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. <i>Cancers</i> , 2020, 12, 611.	1.7	23
54	Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E537-E542.	0.3	4

#	ARTICLE	IF	CITATIONS
55	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020, 78, 661-669.	0.9	74
56	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020, 78, 779-782.	0.9	16
57	ARID1A Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 While ARID1A Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition. <i>Cancers</i> , 2020, 12, 905.	1.7	15
58	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸ Ga-PSMA and ¹¹ C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , 2020, 204, 296-302.	0.2	32
59	Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. <i>Journal of Urology</i> , 2020, 204, 1242-1248.	0.2	14
60	IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5000-5000.	0.8	43
61	Late toxicities and recurrences in patients with clinical stage I nonseminomatous germ cell tumor after one cycle of adjuvant BEP versus primary retroperitoneal lymph node dissection: A 13-years follow-up analysis of a phase III trial cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5512-5512.	0.8	3
62	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 302-302.	0.2	0
63	Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. <i>European Urology</i> , 2019, 75, 310-318.	0.9	129
64	An iterated graph construction and periodic orbits of Hamiltonian delay equations. <i>Journal of Differential Equations</i> , 2019, 266, 2466-2492.	1.1	6
65	Management, Treatment, and Molecular Background of the Growing Teratoma Syndrome. <i>Urologic Clinics of North America</i> , 2019, 46, 419-427.	0.8	14
66	A compactness result for non-local unregularized gradient flow lines. <i>Journal of Fixed Point Theory and Applications</i> , 2019, 21, 1.	0.6	3
67	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 142-150.	0.9	80
68	Prospective comparison of whole-body MRI and ⁶⁸ Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1542-1550.	3.3	47
69	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019, 76, 179-186.	0.9	15
70	Volume Matters: Can We Rely on the Evidence?. <i>European Urology Oncology</i> , 2019, 2, 274-275.	2.6	0
71	Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse. <i>World Journal of Urology</i> , 2019, 37, 2081-2090.	1.2	5
72	Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. <i>European Urology</i> , 2019, 75, 604-611.	0.9	197

#	ARTICLE	IF	CITATIONS
73	The PRIMETEST trial: Interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment.. Journal of Clinical Oncology, 2019, 37, 507-507.	0.8	27
74	Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testis cancer in the salvage setting.. Journal of Clinical Oncology, 2019, 37, 524-524.	0.8	2
75	PSA screening - for whom and when?. Asian Journal of Andrology, 2019, 21, 3.	0.8	0
76	Nichtseminom CS I: Adjuvante Therapie. Springer Reference Medizin, 2019, , 1-7.	0.0	0
77	Nonâ€“risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary. European Urology, 2018, 73, 899-907.	0.9	51
78	Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. European Urology, 2018, 73, 394-405.	0.9	78
79	Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate. Journal of Urology, 2018, 199, 691-698.	0.2	38
80	Current Utilization and Acceptance of Multiparametric MRI in the Diagnosis of Prostate Cancer. A Regional Survey. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2018, 190, 419-426.	0.7	6
81	Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 82.e1-82.e5.	0.8	10
82	Retroperitoneal lymph node dissection in the setting of elevated markers. Current Opinion in Urology, 2018, 28, 435-439.	0.9	7
83	Testicular cancer. Nature Reviews Disease Primers, 2018, 4, 29.	18.1	299
84	Editorial comment. Current Opinion in Urology, 2018, 28, 433-434.	0.9	0
85	Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsyâ€“Are 2 Biopsy Cores per Magnetic Resonance Imaging Lesion Required?. Journal of Urology, 2018, 200, 1030-1034.	0.2	25
86	Discordant prostate specific antigen test results despite WHO assay standardization. International Journal of Biological Markers, 2018, 33, 275-282.	0.7	14
87	Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion. Urologia Internationalis, 2018, 101, 224-231.	0.6	8
88	Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. International Journal of Molecular Sciences, 2018, 19, 590.	1.8	29
89	Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection. Frontiers in Surgery, 2018, 5, 80.	0.6	24
90	Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy. European Urology Focus, 2017, 3, 470-479.	1.6	4

#	ARTICLE	IF	CITATIONS
91	Local systems on the free loop space and finiteness of the Hofer-Zehnder capacity. <i>Mathematische Annalen</i> , 2017, 367, 1403-1428.	0.7	6
92	Testis cancer: some problems still remain unsolved. <i>World Journal of Urology</i> , 2017, 35, 1159-1160.	1.2	0
93	Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 544.e11-544.e23.	0.8	17
94	Magnetic resonance imaging of the prostate at 1.5 versus 3.0 T: A prospective comparison study of image quality. <i>European Journal of Radiology</i> , 2017, 90, 192-197.	1.2	80
95	PD24-03 ONCOLOGICAL OUTCOMES OF PATIENTS TREATED WITH SALVAGE LYMPHNODE DISSECTION (SLND) FOR POSITRON-EMISSION TOMOGRAPHY (PET) POSITIVE PROSTATE CANCER (PCA) RELAPSE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
96	PD53-11 PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) IN STAGE II A/B SEMINOMA PATIENTS WITHOUT ADJUVANT TREATMENT: A PHASE II TRIAL (PRIMETEST). <i>Journal of Urology</i> , 2017, 197, .	0.2	4
97	MP80-20 COMPLICATIONS AND ADJUNCTIVE SURGICAL PROCEDURES IN POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) TO DEFINE A TERTIAL REFERRAL CENTER. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
98	MP81-10 ERECTILE DYSFUNCTION IN 45-OLD GERMAN MEN IN ASSOCIATION WITH RISK FACTORS AND COMORBIDITIES; RESULTS OF THE GERMAN MALE SEX-STUDY. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
99	Positive loops and L^{∞} -contact systolic inequalities. <i>Selecta Mathematica, New Series</i> , 2017, 23, 2491-2521.	0.4	3
100	Targeting mTOR in urothelial cancer—Beating a dead horse or ready for prime time?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 600-601.	0.8	0
101	Vanishing of Rabinowitz Floer homology on negative line bundles. <i>Mathematische Zeitschrift</i> , 2017, 285, 493-517.	0.4	6
102	Re: Reevaluating PSA Testing Rates in the PLCO Trial. <i>European Urology</i> , 2017, 71, 300.	0.9	1
103	Surveillance of Patients with Clinical Stage I Testis Cancer is Safe and Will Remain Unchanged. <i>European Urology</i> , 2017, 71, 130-131.	0.9	2
104	11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer. <i>BJU International</i> , 2017, 120, 337-342.	1.3	4
105	Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1680.	1.8	13
106	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017, 35, 3525-3528.	0.8	56
107	Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. <i>Oncolmmunology</i> , 2016, 5, e1107698.	2.1	28
108	PD15-04 THE ASSOCIATION BETWEEN FAMILY HISTORY AND PROSTATE-SPECIFIC ANTIGEN FROM A LARGE GROUP OF 45-YEAR OLD MEN EMBARKING ON PROSTATE CANCER SCREENING: RESULTS FROM THE PROBASE TRIAL. <i>Journal of Urology</i> , 2016, 195, .	0.2	0

#	ARTICLE	IF	CITATIONS
109	Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 256.e15-256.e21.	0.8	10
110	Cisplatin- Versus Non- Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 331-340.	0.9	12
111	Quality assessment in prostate cancer centers certified by the German Cancer Society. <i>World Journal of Urology</i> , 2016, 34, 665-672.	1.2	23
112	PD12-12 COMPLICATION RATES AFTER RADICAL CYSTECTOMY AFTER RADIOTHERAPY: AN INTERNATIONAL, MULTICENTER RETROSPECTIVE STUDY ON 609 CASES. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
113	Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. <i>European Urology</i> , 2016, 69, 518-525.	0.9	12
114	Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?. <i>European Radiology</i> , 2016, 26, 3858-3864.	2.3	21
115	MRI-Guided In-Bore Biopsy: Differences Between Prostate Cancer Detection and Localization in Primary and Secondary Biopsy Settings. <i>American Journal of Roentgenology</i> , 2016, 206, 92-99.	1.0	54
116	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016, 69, 634-641.	0.9	53
117	Cuplength estimates in Morse cohomology. <i>Journal of Topology and Analysis</i> , 2016, 08, 243-272.	0.2	6
118	Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial. <i>World Journal of Urology</i> , 2016, 34, 215-220.	1.2	23
119	Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4503-4503.	0.8	31
120	PRINCE: A phase III study comparing intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5005-5005.	0.8	4
121	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 386-386.	0.8	0
122	Orderability and the Weinstein conjecture. <i>Compositio Mathematica</i> , 2015, 151, 2251-2272.	0.5	11
123	Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 144.	3.5	27
124	Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09). <i>Oncology</i> , 2015, 89, 70-78.	0.9	26
125	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 76-86.	5.1	323
126	Poor-prognosis Germ Cell Tumours: Room for Improvement. <i>European Urology</i> , 2015, 67, 544-545.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 185-192.	0.9	2
128	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 133-143.	2.0	23
129	E-Learning in Urology: Implementation of the Learning and Teaching Platform CASUS [®] - Do Virtual Patients Lead to Improved Learning Outcomes? A Randomized Study among Students. <i>Urologia Internationalis</i> , 2015, 94, 412-418.	0.6	14
130	The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2061-2068.	1.2	48
131	Prospective Randomized Trial Comparing Magnetic Resonance Imaging (MRI)-guided In-bore Biopsy to MRI-ultrasound Fusion and Transrectal Ultrasound-guided Prostate Biopsy in Patients with Prior Negative Biopsies. <i>European Urology</i> , 2015, 68, 713-720.	0.9	155
132	Guidelines on Testicular Cancer: 2015 Update. <i>European Urology</i> , 2015, 68, 1054-1068.	0.9	538
133	No evidence for adjuvant chemotherapy in high-risk disease. <i>Nature Reviews Urology</i> , 2015, 12, 602-603.	1.9	0
134	False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 23.e15-23.e21.	0.8	25
135	Limitations in using ⁶⁸ Ga-PSMA-PET/CT for detection of recurrent disease following radical prostatectomy in patients with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16110-e16110.	0.8	1
136	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 311-311.	0.8	1
137	Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 335-335.	0.8	0
138	Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4527-4527.	0.8	0
139	Sequential high-dose chemotherapy (HDCT) for relapsed or refractory germ cell cancer (rGCC): Results of a unicentric standardized approach.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15551-e15551.	0.8	0
140	Histological and perioperative outcomes of post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) in advanced germ cell tumors – A single center experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15557-e15557.	0.8	0
141	Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer. <i>International Journal of Molecular Sciences</i> , 2014, 15, 20500-20517.	1.8	30
142	Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO ^{AB} 31/05). <i>BJU International</i> , 2014, 113, 429-436.	1.3	72
143	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014, 113, E137-43.	1.3	31
144	Epidemiological Studies Are Important to Trigger Health Care Decisions. <i>European Urology</i> , 2014, 65, 1107-1108.	0.9	0

#	ARTICLE	IF	CITATIONS
145	Increased signal intensity of prostate lesions on high b-value diffusion-weighted images as a predictive sign of malignancy. <i>European Radiology</i> , 2014, 24, 209-213.	2.3	19
146	Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 966-974.	0.8	33
147	Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer. <i>European Urology</i> , 2014, 66, 655-663.	0.9	16
148	MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. <i>European Radiology</i> , 2014, 24, 2582-2589.	2.3	78
149	Pathological T0 Following Radical Cystectomy with or without Neoadjuvant Chemotherapy: A Useful Surrogate. <i>Journal of Urology</i> , 2014, 191, 898-906.	0.2	51
150	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 130-137.	0.9	27
151	Prospective Evaluation of Magnetic Resonance Imaging Guided In-bore Prostate Biopsy versus Systematic Transrectal Ultrasound Guided Prostate Biopsy in Biopsy Naïve Men with Elevated Prostate Specific Antigen. <i>Journal of Urology</i> , 2014, 192, 1374-1379.	0.2	98
152	Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 395-398.	0.9	12
153	German second-opinion network for testicular cancer: Sealing the leaky pipe between evidence and clinical practice. <i>Oncology Reports</i> , 2014, 31, 2477-2481.	1.2	28
154	Sequential Treatment with Taxanes and Novel Anti-Androgenic Compounds in Castration-Resistant Prostate Cancer. <i>Oncology Research and Treatment</i> , 2014, 37, 492-498.	0.8	9
155	Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. <i>Journal of Clinical Oncology</i> , 2014, 32, 4500-4500.	0.8	9
156	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 336-336.	0.8	1
157	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 353-353.	0.8	2
158	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors. <i>Journal of Clinical Oncology</i> , 2014, 32, 4514-4514.	0.8	0
159	Quality of life in patients undergoing paclitaxel-based second-line treatment of urothelial cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, e15508-e15508.	0.8	1
160	Chemotherapy compared to surgery: Quality-of-life analysis of the German prospective multicenter trial in clinical stage I NSGCT (AÜO AH 01/94). <i>Journal of Clinical Oncology</i> , 2014, 32, 4563-4563.	0.8	0
161	Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. <i>Investigational New Drugs</i> , 2013, 31, 1001-1007.	1.2	30
162	Holmium laser ablation of the prostate (HoLAP): intermediate-term results of 144 patients. <i>World Journal of Urology</i> , 2013, 31, 1253-1259.	1.2	11

#	ARTICLE	IF	CITATIONS
163	Translated points and Rabinowitz Floer homology. <i>Journal of Fixed Point Theory and Applications</i> , 2013, 13, 201-214.	0.6	11
164	Exponential decay for sc-gradient flow lines. <i>Journal of Fixed Point Theory and Applications</i> , 2013, 13, 571-586.	0.6	2
165	3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization. <i>Acta Radiologica</i> , 2013, 54, 1224-1229.	0.5	11
166	Re: Strategy for Detection of Prostate Cancer Based on Relation Between Prostate Specific Antigen at Age 40-55 and Long Term Risk of Metastasis: Case-control Study. <i>European Urology</i> , 2013, 64, 681-682.	0.9	1
167	Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 495-500.	0.9	20
168	Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?. <i>European Urology</i> , 2013, 64, 355-357.	0.9	29
169	Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1770-1779.	0.8	68
170	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. <i>European Urology</i> , 2013, 63, 717-723.	0.9	104
171	Prospective Randomized Evaluation of Risk-adapted Prostate-specific Antigen Screening in Young Men: The PROBSE Trial. <i>European Urology</i> , 2013, 64, 873-875.	0.9	43
172	Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme. <i>European Urology</i> , 2013, 63, 977-982.	0.9	70
173	Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3490-3493.	0.8	124
174	The Conley-Zehnder indices of the rotating Kepler problem. <i>Mathematical Proceedings of the Cambridge Philosophical Society</i> , 2013, 154, 243-260.	0.3	15
175	Canadian consensus guidelines for the management of testicular germ cell cancer. <i>Canadian Urological Association Journal</i> , 2013, 4, 19.	0.3	119
176	Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00).. <i>Journal of Clinical Oncology</i> , 2013, 31, 250-250.	0.8	5
177	Options and limitations using 11c-acetate PET/CT imaging for detection of recurrent disease following radical prostatectomy in patients with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e16003-e16003.	0.8	0
178	Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4524-4524.	0.8	0
179	Design of Testis Cancer Trials: Who Knows Best?. <i>Journal of Clinical Oncology</i> , 2012, 30, 3145-3146.	0.8	1
180	Randomized Phase III Study Comparing Paclitaxel-Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983. <i>Journal of Clinical Oncology</i> , 2012, 30, 792-799.	0.8	90

#	ARTICLE	IF	CITATIONS
181	A Variational Approach to Givental's Nonlinear Maslov Index. <i>Geometric and Functional Analysis</i> , 2012, 22, 1033-1050.	0.6	8
182	Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk. <i>Archives of Toxicology</i> , 2012, 86, 1369-1378.	1.9	32
183	Management of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma: When to Start and When to Stop Targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 213-218.	0.9	9
184	Contemporary Management of Postchemotherapy Testis Cancer. <i>European Urology</i> , 2012, 62, 867-876.	0.9	96
185	Infinitely many leaf-wise intersections on cotangent bundles. , 2012, 30, 168-181.		9
186	18 URETHROPLASTY USING SMALL INTESTINAL SUBMUCOSA (SIS) AS ONLAY-PATCH " RESULTS OF 49 CONSECUTIVE PATIENTS. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
187	Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 762-771.	0.8	6
188	Comparison of different mathematical models of diffusion-weighted prostate MR imaging. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1468-1474.	1.0	55
189	On a theorem by Ekeland-Hofer. <i>Israel Journal of Mathematics</i> , 2012, 187, 485-491.	0.4	3
190	Global Surfaces of Section in the Planar Restricted 3-Body Problem. <i>Archive for Rational Mechanics and Analysis</i> , 2012, 204, 273-284.	1.1	24
191	Residual Tumor Size and IGCCCG Risk Classification Predict Additional Vascular Procedures in Patients with Germ Cell Tumors and Residual Tumor Resection: A Multicenter Analysis of the German Testicular Cancer Study Group. <i>European Urology</i> , 2012, 61, 403-409.	0.9	82
192	The Contemporary Role of Chemotherapy for Advanced Testis Cancer: A Systematic Review of the Literature. <i>European Urology</i> , 2012, 61, 1212-1221.	0.9	26
193	Contact geometry of the restricted three-body problem. <i>Communications on Pure and Applied Mathematics</i> , 2012, 65, 229-263.	1.2	46
194	Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene. <i>Archives of Toxicology</i> , 2012, 86, 195-203.	1.9	14
195	Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4590-4590.	0.8	2
196	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 172-172.	0.8	1
197	Efficacy of abiraterone acetate in the treatment of castration-resistant prostate cancer: Early results from the German compassionate-use program.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15195-e15195.	0.8	0
198	Repeat transrectal ultrasound biopsies with additional targeted cores according to results of functional prostate MRI detects high-risk prostate cancer in patients with previous negative biopsy and increased PSA - a pilot study. <i>Anticancer Research</i> , 2012, 32, 1087-92.	0.5	16

#	ARTICLE	IF	CITATIONS
199	Testicular germ cell tumors: pathogenesis, diagnosis and treatment. <i>Nature Reviews Endocrinology</i> , 2011, 7, 43-53.	4.3	97
200	830 PATHOHISTOLOGICAL FINDINGS IN PATIENTS WITH NONSEMINOMATOUS GERM CELL TUMOURS (NSGCT) WHO UNDERGO POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) FOR SMALL TUMOURS. <i>Journal of Urology</i> , 2011, 185, .	0.2	14
201	Retrograde balloon dilation >10 weeks after renal transplantation for transplant ureter stenosis – our experience and review of the literature. <i>Arab Journal of Urology Arab Association of Urology</i> , 2011, 9, 93-99.	0.7	7
202	Sunitinib for the treatment of metastatic renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2011, 37, 178-184.	3.4	55
203	The requirements of a specialist Prostate Cancer Unit: A discussion paper from the European School of Oncology. <i>European Journal of Cancer</i> , 2011, 47, 1-7.	1.3	45
204	Diagnosis, Staging, and Risk Factors: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. <i>Urology</i> , 2011, 78, S427-S434.	0.5	4
205	Postchemotherapy Retroperitoneal Residual Tumor Resection for Minimal Residual Disease. <i>European Urology Supplements</i> , 2011, 10, e64-e70.	0.1	0
206	Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?. <i>Current Opinion in Urology</i> , 2011, 21, 434-439.	0.9	7
207	Histopathological and molecular features of late relapses in non-€seminomas. <i>BJU International</i> , 2011, 107, 936-943.	1.3	25
208	EAU Guidelines on Testicular Cancer: 2011 Update. <i>European Urology</i> , 2011, 60, 304-319.	0.9	333
209	Prognostic Factors in Second-Line Treatment of Urothelial Cancers With Gemcitabine and Paclitaxel (German Association of Urological Oncology Trial AB20/99). <i>European Urology</i> , 2011, 60, 1087-1096.	0.9	25
210	Re: Conventional-Dose Versus High-Dose Chemotherapy as First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database. <i>European Urology</i> , 2011, 60, 1124-1125.	0.9	3
211	Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2191-2198.	0.8	215
212	Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 673-678.	0.7	50
213	Non-displaceable contact embeddings and infinitely many leaf-wise intersections. <i>Journal of Symplectic Geometry</i> , 2011, 9, 271-284.	0.3	6
214	Treatment of Nonseminoma: Stage I. , 2011, , 147-166.		0
215	Postchemotherapy Retroperitoneal Lymph Node Dissection. , 2011, , 225-236.		0
216	On nonseparating contact hypersurfaces in symplectic 4-€manifolds. <i>Algebraic and Geometric Topology</i> , 2010, 10, 697-737.	0.1	18

#	ARTICLE	IF	CITATIONS
217	Rs710521 [A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. Archives of Toxicology, 2010, 84, 967-978.	1.9	37
218	Extraperitoneal laparo-endoscopic single-site radical prostatectomy: first experience. World Journal of Urology, 2010, 28, 705-708.	1.2	23
219	Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. Histochemistry and Cell Biology, 2010, 134, 197-204.	0.8	30
220	Burden or Relief: Do Second-Opinion Centers Influence the Quality of Care Delivered to Patients with Testicular Germ Cell Cancer?. European Urology, 2010, 57, 867-872.	0.9	28
221	Organ-Sparing Surgery for Adult Testicular Tumours: A Systematic Review of the Literature. European Urology, 2010, 57, 780-790.	0.9	173
222	Cup-length estimates for leaf-wise intersections. Mathematical Proceedings of the Cambridge Philosophical Society, 2010, 149, 539-551.	0.3	12
223	Erratum for "On the Extrinsic Topology of Lagrangian Submanifolds" International Mathematics Research Notices, 2010, 2010, 1363-1369.	0.5	7
224	Imaging Studies in Metastatic Urogenital Cancer Patients Undergoing Systemic Therapy: Recommendations of a Multidisciplinary Consensus Meeting of the Association of Urological Oncology of the German Cancer Society. Urologia Internationalis, 2010, 85, 1-10.	0.6	45
225	LEAF-WISE INTERSECTIONS AND RABINOWITZ FLOER HOMOLOGY. Journal of Topology and Analysis, 2010, 02, 77-98.	0.2	43
226	Periodic Bounce Orbits of Prescribed Energy. International Mathematics Research Notices, 2010, , .	0.5	2
227	638 COMPLICATIONS OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PCRPLND) IN ADVANCED NONSEMINOMATOUS GERM CELL TUMORS " FIRST RESULTS OF THE GERMAN TESTICULAR CANCER STUDY GROUP. Journal of Urology, 2010, 183, .	0.2	0
228	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 492-499.	0.8	42
229	Spectral invariants in Rabinowitz-Floer homology and global Hamiltonian perturbations. Journal of Modern Dynamics, 2010, 4, 329-357.	0.2	19
230	Infertility and testis cancer. , 2010, , 176-185.		0
231	On the Weinstein conjecture in higher dimensions. Commentarii Mathematici Helvetici, 2009, 84, 429-436.	0.4	20
232	Germ Cell Tumors of the Gonads: A Selective Review Emphasizing Problems in Drug Resistance and Current Therapy Options. Oncology, 2009, 76, 77-84.	0.9	14
233	Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Testicular Cancer: Radical or Modified Template Resection. European Urology, 2009, 55, 217-226.	0.9	179
234	Surgery for Metastatic Urothelial Carcinoma with Curative Intent: The German Experience (AUO AB) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.9	117

#	ARTICLE	IF	CITATIONS
235	Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. <i>BJU International</i> , 2009, 104, 48-52.	1.3	84
236	Retroperitoneal lymph node dissection after chemotherapy. <i>BJU International</i> , 2009, 104, 1404-1412.	1.3	31
237	Cell-Free Circulating DNA: Diagnostic Value in Patients With Testicular Germ Cell Cancer. <i>Journal of Urology</i> , 2009, 181, 363-371.	0.2	79
238	CpG Island Hypermethylation of Cell-Free Circulating Serum DNA in Patients With Testicular Cancer. <i>Journal of Urology</i> , 2009, 182, 324-329.	0.2	77
239	CPG ISLAND HYPERMETHYLATION IN CELL-FREE, CIRCULATING SERUM DNA PATIENTS WITH TESTICULAR CANCER - A POTENTIAL BIOMARKER. <i>Journal of Urology</i> , 2009, 181, 200-200.	0.2	2
240	COMPLICATIONS OF POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR ADVANCED TESTIS CANCER. <i>Journal of Urology</i> , 2009, 181, 325-326.	0.2	0
241	Floer homology for negative line bundles and Reeb chords in prequantization spaces. <i>Journal of Modern Dynamics</i> , 2009, 3, 407-456.	0.2	4
242	Maligne Hodentumoren. , 2009, , 637-738.		0
243	A nondisplaceable Lagrangian torus in T^2 . <i>Communications on Pure and Applied Mathematics</i> , 2008, 61, 1046-1051.	1.2	15
244	Analysis of the <i>DND1</i> gene in men with sporadic and familial testicular germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 247-252.	1.5	37
245	Re: Cystectomy for Transitional Cell Carcinoma of the Bladder: Results of a Surgery Only Series in the Neobladder Era. <i>European Urology</i> , 2008, 53, 208-209.	0.9	2
246	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. <i>European Urology</i> , 2008, 53, 478-496.	0.9	488
247	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. <i>European Urology</i> , 2008, 53, 497-513.	0.9	243
248	Editorial Comment on: Laparoscopic Retroperitoneal Lymph Node Dissection: Does It Still Have a Role in the Management of Clinical Stage I Nonseminomatous Testis Cancer? A European Perspective. <i>European Urology</i> , 2008, 54, 1016-1017.	0.9	2
249	European Association of Urology Renal Cell Carcinoma (RCC) Supplement: Chairman's Introduction. <i>European Urology Supplements</i> , 2008, 7, 35.	0.1	0
250	Treatment Approaches in Renal Cell Carcinoma: Past, Present, and Future Perspectives. <i>European Urology Supplements</i> , 2008, 7, 36-45.	0.1	5
251	A NOVEL DIAGNOSTIC MARKER: CELL-FREE CIRCULATING DNA IN SERUM OF PATIENTS WITH TESTICULAR CANCER. <i>Journal of Urology</i> , 2008, 179, 272-272.	0.2	0
252	Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 2966-2972.	0.8	305

#	ARTICLE	IF	CITATIONS
253	Radiofrequency Ablation of Renal Tumors Improved by Preoperative ex-Vivo Computer Simulation Model. <i>Journal of Endourology</i> , 2007, 21, 886-890.	1.1	8
254	Clarifying the indications for adjuvant chemotherapy in muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2007, 4, 184-185.	1.4	1
255	Renal Cell Carcinoma With Tumor Thrombus Extension Into the Vena Cava: Prospective Long-Term Followup. <i>Journal of Urology</i> , 2007, 177, 1703-1708.	0.2	188
256	Seminal vesicle-sparing perineal radical prostatectomy improves early functional results in patients with low-risk prostate cancer. <i>BJU International</i> , 2007, 100, 070902212121001-???.	1.3	17
257	Management of Stage I Testis Cancer. <i>European Urology</i> , 2007, 51, 34-44.	0.9	38
258	1001: Retroperitoneal Residual Tumor (RTR) Resection for Testicular Cancer - Template Instead of Full Bilateral Resection. <i>Journal of Urology</i> , 2007, 177, 331-331.	0.2	4
259	1304: The Tumor Thrombus Level in Patients with Renal Cell Carcinoma Extending to the INF. Vena Cava has a Prognostic Influence on Long Term Survival. <i>Journal of Urology</i> , 2007, 177, 429-429.	0.2	0
260	Organ-Sparing Surgery for Testicular Lesions. <i>European Urology Supplements</i> , 2006, 5, 522-524.	0.1	15
261	Investigation of the glidant properties of compacted colloidal silicon dioxide by angle of repose and X-ray photoelectron spectroscopy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2006, 63, 356-359.	2.0	31
262	Characterisation of the adsorption sites of hydrogen on Pt/C fuel cell catalysts. <i>Catalysis Today</i> , 2006, 114, 418-421.	2.2	42
263	Volume Mattersâ€™but It Should be Measured Well!. <i>European Urology</i> , 2006, 50, 194-195.	0.9	0
264	Surgery is an Essential Part of Salvage Treatment in Refractory Germ Cell Tumors. <i>European Urology</i> , 2006, 50, 893-894.	0.9	5
265	A risk-adapted approach to the treatment of stage I seminoma. <i>Nature Reviews Urology</i> , 2006, 3, 248-249.	1.4	0
266	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. <i>Human Molecular Genetics</i> , 2006, 15, 443-451.	1.4	138
267	Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. <i>GMS German Medical Science</i> , 2006, 4, Doc02.	2.7	4
268	Guidelines on Testicular Cancer. <i>European Urology</i> , 2005, 48, 885-894.	0.9	185
269	Adjuvant Cisplatin Plus Methotrexate Versus Methotrexate, Vinblastine, Epirubicin, and Cisplatin in Locally Advanced Bladder Cancer: Results of a Randomized, Multicenter, Phase III Trial (AUO-AB 05/95). <i>Journal of Clinical Oncology</i> , 2005, 23, 4963-4974.	0.8	103
270	A novel component of the ubiquitin pathway, ubiquitin carboxyl extension protein 1 is overexpressed in prostate cancer. <i>International Journal of Molecular Medicine</i> , 2005, 15, 183.	1.8	0

#	ARTICLE	IF	CITATIONS
271	Cellular retinoic acid-binding protein 2 is down-regulated in prostate cancer. <i>International Journal of Oncology</i> , 2005, 27, 1273.	1.4	9
272	LATE RELAPSE OF TESTICULAR GERM CELL NEOPLASMS: A DESCRIPTIVE ANALYSIS OF 122 CASES. <i>Journal of Urology</i> , 2005, 173, 824-829.	0.2	125
273	Modified ureterosigmoidostomy (Mainz Pouch II) in different age groups and with different techniques of ureteric implantation. <i>BJU International</i> , 2004, 94, 345-349.	1.3	27
274	Primary extragonadal germ cell tumor of the prostate in a young man. <i>International Journal of Urology</i> , 2004, 11, 671-673.	0.5	7
275	Health-Related Quality-of-Life Following Modified Ureterosigmoidostomy (Mainz Pouch II) as Continent Urinary Diversion. <i>European Urology</i> , 2004, 46, 591-597.	0.9	23
276	Late relapse of testicular cancer. <i>World Journal of Urology</i> , 2004, 22, 47-54.	1.2	31
277	Resection of retroperitoneal residual tumor after chemotherapy for testicular cancer indication and surgical techniques. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 79-85.	2.0	8
278	Inelastic neutron scattering studies of hydrogen on fuel cell catalysts. <i>Vibrational Spectroscopy</i> , 2004, 35, 179-182.	1.2	15
279	Telomerase Pulsed Dendritic Cells for Immunotherapy for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2004, 171, 114-119.	0.2	30
280	Prediction of Necrosis After Chemotherapy of Advanced Germ Cell Tumors: Results of a Prospective Multicenter Trial of the German Testicular Cancer Study Group. <i>Journal of Urology</i> , 2004, 171, 1835-1838.	0.2	125
281	925: Risk-Adapted Treatment is Not Superior to Surgery – A Quality of Life Analysis of the German Prospective Multicenter Trial in Clinical Stage I NSGCT. <i>Journal of Urology</i> , 2004, 171, 245-246.	0.2	0
282	Phase I/II Trial of Dendritic Cells Pulsed with Telomerase.. <i>Blood</i> , 2004, 104, 1353-1353.	0.6	0
283	Surgery in Metastatic Testicular Cancer. <i>European Urology</i> , 2003, 44, 233-244.	0.9	35
284	Angiogenetic Protooncogene ets-1 Induced Neovascularization Is Involved in the Metastatic Process of Testicular Germ Cell Tumors. <i>European Urology</i> , 2003, 44, 329-336.	0.9	26
285	Corporoplasty for Advanced Peyronie's Disease Using Venous And/or Dermis Patch Grafting: New Surgical Technique And Long-term Patient Satisfaction. <i>Journal of Urology</i> , 2003, 169, 981-984.	0.2	28
286	A New Form of Noninvasive Wound Closure With a Surgical Zipper. <i>Journal of Urology</i> , 2003, 169, 1785-1786.	0.2	6
287	Complications of Primary Nerve Sparing Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Experience of the German Testicular Cancer Study Group. <i>Journal of Urology</i> , 2003, 169, 1710-1714.	0.2	217
288	Allogeneic Dendritic Cells Fused with Tumor Cells: Preclinical Results and Outcome of a Clinical Phase I/II Trial in Patients with Metastatic Renal Cell Carcinoma. <i>Human Gene Therapy</i> , 2003, 14, 483-494.	1.4	141

#	ARTICLE	IF	CITATIONS
289	Predictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review. <i>Journal of Clinical Oncology</i> , 2003, 21, 4092-4099.	0.8	158
290	Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate. <i>Journal of Clinical Oncology</i> , 2003, 21, 2869-2875.	0.8	157
291	Risk Factors for Relapse in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: Results of the German Testicular Cancer Study Group Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 1505-1512.	0.8	289
292	Surgery in testis cancer: laparoscopic and open techniques. <i>Current Opinion in Urology</i> , 2002, 12, 435-440.	0.9	10
293	Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 637-644.	2.0	98
294	ORGAN SPARING SURGERY FOR MALIGNANT GERM CELL TUMOR OF THE TESTIS. <i>Journal of Urology</i> , 2001, 166, 2161-2165.	0.2	318
295	Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy—Results From an International Study Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 2647-2657.	0.8	264
296	Erythropoetin in Urologic Oncology. <i>European Urology</i> , 2001, 39, 1-8.	0.9	21
297	Therapeutic Vaccination against Metastatic Carcinoma by Expression-Modulated and Immunomodified Autologous Tumor Cells: A First Clinical Phase I/II Trial. <i>Human Gene Therapy</i> , 2001, 12, 267-278.	1.4	84
298	Inelastic Neutron Scattering Investigation of the Nature of Surface Sites Occupied by Hydrogen on Highly Dispersed Platinum on Commercial Carbon Black Supports. <i>Journal of Catalysis</i> , 2000, 196, 174-179.	3.1	32
299	Eukaryotic Initiation Factor 3 p110 mRNA Is Overexpressed in Testicular Seminomas. <i>American Journal of Pathology</i> , 2000, 157, 1597-1604.	1.9	54
300	SALVAGE SURGERY OF CHEMOREFRACTORY GERM CELL TUMORS WITH ELEVATED TUMOR MARKERS. <i>Journal of Urology</i> , 2000, 164, 381-384.	0.2	121
301	Loss of heterozygosity, differentiation, and clonality in microdissected male germ cell tumours. <i>Journal of Pathology</i> , 1999, 188, 389-394.	2.1	28
302	Risk factors for relapse in stage I non-seminomatous germ-cell tumors: Preliminary results of the German multicenter trial. , 1999, 83, 828-830.		16
303	Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. <i>Urology</i> , 1999, 53, 808-811.	0.5	163
304	Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. <i>Urology</i> , 1999, 54, 714-718.	0.5	28
305	SIMS/XPS Study on the Deactivation and Reactivation of B-MFI Catalysts Used in the Vapour-Phase Beckmann Rearrangement. <i>Journal of Catalysis</i> , 1998, 176, 561-568.	3.1	50
306	FLUORESCENCE IN SITU HYBRIDIZATION ON NUCLEI FROM PARAFFIN-EMBEDDED TISSUE IN LOW STAGE PURE EMBRYONAL CARCINOMA OF THE TESTIS. <i>Journal of Urology</i> , 1998, 159, 240-244.	0.2	25

#	ARTICLE	IF	CITATIONS
307	Efficient photo-assisted Fenton catalysis mediated by Fe ions on Nafion membranes active in the abatement of non-biodegradable azo-dye. <i>Chemical Communications</i> , 1998, , 1493-1494.	2.2	80
308	Management of Complete Ureteral Replacement: Experiences and Review of the Literature. <i>Scandinavian Journal of Urology and Nephrology</i> , 1997, 31, 383-388.	1.4	26
309	Prognostic risk factors in low stage testicular germ cell tumors. <i>Cancer</i> , 1997, 79, 1646-1646.	2.0	0
310	MIB-1 immunohistochemistry in clinical Stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. , 1997, 79, 1710-1716.		51
311	Long-Term Results of Internal Urethrotomy. <i>Journal of Urology</i> , 1996, 156, 1611-1614.	0.2	167
312	Tumor Proliferative Activity is Predictive of Pathological Stage in Clinical Stage a Nonseminomatous Testicular Germ Cell Tumors. <i>Journal of Urology</i> , 1996, 155, 579-586.	0.2	46
313	Tumor Proliferative Activity is Predictive of Pathological Stage in Clinical Stage a Nonseminomatous Testicular Germ Cell Tumors. <i>Journal of Urology</i> , 1996, , 579-586.	0.2	1
314	Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage a nonseminomatous testicular germ cell tumor at low risk for occult metastasis. <i>Cancer</i> , 1995, 75, 844-850.	2.0	34
315	Ectopic ureters and ureteroceles in adults. <i>Urology</i> , 1995, 45, 870-874.	0.5	27
316	Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors. <i>Cancer</i> , 1994, 74, 1335-1341.	2.0	32
317	Flow-cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical-stage-I non-seminomatous testicular germ-cell tumors. <i>International Journal of Cancer</i> , 1994, 57, 628-633.	2.3	30
318	Oxidative coupling of methane. The effect of alkali chlorides on molybdate based catalyst leading to high selectivity in C3-product formation. <i>Catalysis Letters</i> , 1993, 18, 15-26.	1.4	5
319	Oxidative coupling of methane over molybdates: catalyst performance and characterization. <i>The Journal of Physical Chemistry</i> , 1992, 96, 1344-1349.	2.9	11